ALT1 * logo

Altimmune BMV:ALT1 * Stock Report

Last Price

Mex$170.00

Market Cap

Mex$11.8b

7D

-6.6%

1Y

9.7%

Updated

23 Dec, 2024

Data

Company Financials +

ALT1 * Stock Overview

A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. More details

ALT1 * fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Altimmune, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Altimmune
Historical stock prices
Current Share PriceUS$170.00
52 Week HighUS$246.00
52 Week LowUS$113.09
Beta0.15
1 Month Change-4.76%
3 Month Changen/a
1 Year Change9.68%
3 Year Change-7.61%
5 Year Changen/a
Change since IPO-60.47%

Recent News & Updates

Recent updates

Shareholder Returns

ALT1 *MX BiotechsMX Market
7D-6.6%0%0%
1Y9.7%0%0%

Return vs Industry: ALT1 * exceeded the MX Biotechs industry which returned -1.9% over the past year.

Return vs Market: ALT1 * exceeded the MX Market which returned -14% over the past year.

Price Volatility

Is ALT1 *'s price volatile compared to industry and market?
ALT1 * volatility
ALT1 * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ALT1 *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ALT1 *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199759Vipin Gargaltimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune, Inc. Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
ALT1 * fundamental statistics
Market capMex$11.78b
Earnings (TTM)-Mex$2.08b
Revenue (TTM)Mex$1.04m

Over9,999x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALT1 * income statement (TTM)
RevenueUS$52.00k
Cost of RevenueUS$79.35m
Gross Profit-US$79.30m
Other ExpensesUS$24.22m
Earnings-US$103.52m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.46
Gross Margin-152,503.85%
Net Profit Margin-199,076.92%
Debt/Equity Ratio0%

How did ALT1 * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:39
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Altimmune, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Joshua SchimmerEvercore ISI
Liisa BaykoEvercore ISI